Abstract We studied resistance to endocrine and HER2-targeted therapies using a xenograft model of estrogen receptor positive (ER)/HER2-overexpressing breast cancer. Here, we report a novel phenotype of drug resistance in this model. MCF7/HER2-18 xenografts were treated with endocrine therapy alone or in combination with lapatinib and trastuzumab (LT) to inhibit HER2. Archival tumor tissues were stained with hematoxylin and eosin and with mucicarmine. RNA extracted from tumors at early time points and late after acquired resistance were analyzed for mucin4 (MUC4) expression by microarray and quantitative reverse transcriptase-PCR. Protein expression of the MUC4, ER, and HER2 signaling pathways was measured by immunohistochemistry and western blotting. The combination of the potent anti-HER2 regimen LT with either tamoxifen (Tam ? LT) or estrogen deprivation (ED ? LT) can cause complete eradication of ER-positive/HER2-overexpressing tumors in mice. Tumors developing resistance to this combination, as well as those acquiring resistance to endocrine therapy alone, exhibited a distinct histological and molecular phenotype-a striking increase in mucin-filled vacuoles and upregulation of several mucins including MUC4. At the onset of resistance, MUC4 mRNA and protein were increased. These tumors also showed upregulation and reactivation of HER2 signaling, while losing ER protein and the estrogenregulated gene progesterone receptor. Mucins are upregulated in a preclinical model of ER-positive/HER2-overexpressing breast cancer as resistance develops to the combination of endocrine and anti-HER2 therapy. These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive.
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Background
Found in *70 % of breast cancers, estrogen receptor-alpha (ER) generally identifies a more indolent tumor phenotype that can be targeted with endocrine therapy [either tamoxifen (Tam) or estrogen deprivation (ED) via aromatase inhibitors]. Crosstalk between ER and human epidermal growth factor receptor-2 (HER2/neu/c-ErbB2) contributes to endocrine resistance in preclinical models [1, 2] and combining endocrine therapy (Tam or ED) with drugs targeting the HER pathway can significantly delay resistance by inhibiting crosstalk in preclinical models [3] [4] [5] [6] . This has been shown to be an effective treatment strategy in clinical trials [7] [8] [9] [10] . We have modeled this phenomenon by growing MCF7 cells that stably overexpress HER2 (MCF7/ HER2) as xenograft tumors. These tumors (MCF7/HER2-18) have been shown previously to be more endocrine resistant than MCF7 wild-type xenografts. Giving tamoxifen stimulates growth, exhibiting de novo resistance in these tumors. ED therapy results in transient response as tumors rapidly acquire resistance [11] . ED-resistant tumors alter their molecular phenotype by losing ER expression and upregulating HER2 signaling. These data suggest that both ER and HER2 need to be targeted therapeutically in ERpositive tumors with HER2 amplification or overexpression.
Currently, two FDA-approved medications specifically target HER2: the monoclonal antibody trastuzumab and the dual kinase inhibitor lapatinib. Adding a single anti-HER2 agent to endocrine therapy can temporarily restore growth inhibition, but is inadequate to block HER2 signaling to fully eradicate tumors [1, 3] . Combining both the anti-HER2 drugs with endocrine therapy not only completely shuts off ER-HER2 signaling and crosstalk but also results in complete regression of most of these xenograft tumors in mice [12] . However, a few tumors eventually acquire resistance, indicating that these tumors have reactivation of HER2 or bypass sustained HER2 inhibition with escape mechanisms to drive tumor growth. In this report, we present a novel and striking phenotypic shift with the model system of MCF7/HER2 tumors resistant to a combination of endocrine and anti-HER2 therapy.
Materials and methods

Cell lines and antibodies
Generation and growth conditions of MUC4-positive CD18/HPAF, MCF7/HER2-18, and MCF7/HER2-11 cell lines were previously described [13] . Anti-MUC4 (8G7) was generated as previously described [14] with additional aliquots purchased along with anti-ERa (H-184) from Santa Cruz Biotechnologies (Santa Cruz, CA). Antiphospho-HER2 (Y1248) was purchased from Millipore (Billerica, MA). Polyclonal antibodies against HER2, phospho-Akt (pThr308), total Akt, phospho-MAPK (pThr202/ pTyr204), total MAPK, and b-actin were purchased from Cell Signaling Technology (Danvers, MA).
Human breast cancer xenograft tumors
Xenograft tumors of MCF7/HER2-18, MCF7/HER2-11, and MCF7 wild-type with cell lines previously generated in nu/nu athymic nude mice treated with continued E2-supplementation (control), endocrine treatment alone (Tamoxifen or ED), or in combination with the anti-HER2 regimen (E2 ? LT, Tam ? LT, ED ? LT) for MCF7/ HER2-18 only, as previously reported [12] . Only two tumors developed resistance to the ED ? LT regimen after [200 days. One of these tumors demonstrated a more stable phenotype and was transplantable. 2-mm 3 fragments of this tumor were transplanted into an additional set of nude mice and harvested. For this study, transplants of the more stable and transplantable tumor were collected and combined with the original tumor and considered the ED ? LT-resistant group. These archival tumors were stored in liquid nitrogen or were formalin-fixed and paraffin-embedded (FFPE).
Histological staining, immunohistochemistry (IHC), and immunofluorescence (IF) 5-lm sections were stained with hematoxylin and eosin (H&E) or mucicarmine, or were used for IHC. Cell pellets were made by growing cells in 10-cm culture dishes at *95 % confluency, washing them with pH 7.4 phosphate buffered saline (PBS), and detaching them with Versene (Lonza, Basel, Switzerland). Cells were washed two additional times with PBS, fixed for 2 h in 10 % neutral buffered formalin, and then resuspended in PBS. Cells were pelleted to remove PBS and resuspended into 4 % agar. Cells were refrigerated for 30 min and then embedded into paraffin. MUC4 IHC was performed following a protocol previously described [14] , with the modification of using a Mouse-on-Mouse kit (Vector Labs, Burlingame, CA) to reduce background staining. Tumors were scored using intensity scores (IS: 1-3) and percentage scores (PS: 0-100). A histoscore for each tumor was calculated by multiplying IS by PS. Slides were also dual stained by combining the IHC protocol for HER2 (rabbit antibody) as before [1] and the MUC4 (mouse antibody) IHC protocol. Furthermore, slides were stained for IF by using antimouse-AlexaFluor568 (Invitrogen, Carlsbad, CA) and antirabbit-Fluorescein-Isothiocyanate (Vector Labs). Representative IF images were obtained with an SP5 confocal microscope (Leica, Bannockburn, IL) using a 639 oil immersion objective with LAS Software (Leica).
Microarray analysis
Mucin family gene expression in endocrine-resistant MCF7/HER2-18 and MCF-7 wild-type tumors was extracted from a previous study [15] . Arrays were normalized and compared using DNA Chip Analyzer software (dChip, www.dChip.org). Two-sample t tests of log-transformed data were performed as criteria for determining significant differences in mean gene mRNA levels between groups. Expression values were visualized as heatmaps using Java TreeView [16] . An additional MCF7/HER2-18 expression microarray was generated using similar methods to look specifically at MUC4 levels.
RNA isolation and quantitative real-time PCR assay
Tumor RNA was isolated with the EZ-1 kit (Qiagen, Germantown, MD) and the Biorobot EZ1 (Qiagen) according to manufacturer's specifications. CD18/HPAF RNA was isolated using the RNeasy Kit (Qiagen) following manufacturer's protocol. cDNA was made from RNA using SuperScript III Reverse Transcriptase (Invitrogen) according to manufacturer's directions. MUC4-specific primers were designed using Entrez ID NM018406 by Primer Express (Applied Biosystems, Carlsbad, CA). The MUC4 forward primer was 5 0 TCACTCTGGAGATTCTAGCAAGAAGT 3 0 and the reverse primer was 5 0 ACTGTGGTCTGCCAT TGCAAT 3 0 . b-Actin-specific primers were described previously [17] . All the primers were synthesized by Eurogentec (San Diego, CA). The qPCR was performed on Applied Biosystems 7700 using SYBR Green PCR Master Mix (Applied Biosystems) following manufacturer's instructions. MUC4 mRNA expression was normalized to b-actin using the comparative Ct method [18] , calculated as a fold change relative to a representative E2-stimulated MCF7/ HER2-18 tumor, and log2-transformed.
Immunoblotting
Tumor extracts were generated by homogenizing frozen tissue in Reverse Phase Protein Array buffer [1, 19] . Fifteen micrograms of protein extracts were loaded and separated on precast 8 % Tris-glycine sodium dodecyl sulfate (SDS)-polyacrylamide gels (Invitrogen), before transferring to nitrocellulose membrane via iBlot (Invitrogen) as per manufacturer's directions. Membranes were blocked in 5 % milk solution and then incubated with primary antibodies overnight at 4°C. After washing, membranes were incubated for an hour in appropriate horseradish peroxidase-labeled secondary antibodies at room temperature. After additional washes, chemiluminescence solution (GE Healthcare, Pittsburgh, PA) was used as per manufacturer's specifications. Membranes were exposed to film and quantified on a gel imager (Alpha Innotech, Santa Clara, CA). Protein expression was normalized to b-actin and log2-transformed.
Statistical analysis
The statistical significance of the difference between two means of data was analyzed using two-sided Student's t test for normally distributed samples. For the IHC data, as some data sets failed the Shapiro-Wilk normality test [20] , the two-sided generalized Wilcoxon rank sum test [21] was used. All statistical analyses were performed using R [22] . Charts were plotted with mean ± SE. A p value of \0.05 was considered significant. 
Results
Mucinated phenotype in drug-resistant xenograft tumors
We have previously shown [11, 12] that MCF7/HER2-18 xenografts are de novo resistant to Tam treatment and rapidly acquire resistance to ED, and adding potent dualagent anti-HER2 treatment (LT) can delay this effect and even completely eradicate some tumors (Fig. 1a) . Importantly, we observed striking histological changes in these tumors resistant to Tam and ED, alone or in combination with LT (Fig. 1b) . H&E staining of tumor sections in these groups detected the presence of multiple occupied vacuoles. This phenotype was not observed in E2-stimulated tumors alone or with LT. Mucicarmine staining confirmed the presence of mucin in these vacuoles, which were primarily intracellular, exhibiting cellular morphology similar to signet ring cells (see arrowheads) [23] .
Expression of MUC4 mRNA in resistant tumors
We analyzed previously published expression microarrays of endocrine resistant MCF7/HER2-18 and wild-type MCF7 tumors for mucin gene expression [15] . mRNA of multiple mucin genes were upregulated in endocrineresistant tumors when compared to E2-stimulated controls (Fig. 2) . MUC4 and MUC5AC mRNA levels were increased in Tam-and ED-resistant MCF7/HER2-18 tumors but not in Tam-and ED-resistant wild-type MCF7 tumors. Due to its reported role in HER2 stability and signaling [24, 25] , we next focused on MUC4 and tested for its expression in tumors treated with endocrine therapy with LT. MUC4 expression was dramatically increased in tumors resistant to endocrine therapy alone (Tam or ED) and in combination with LT when compared to E2-stimulated control tumors alone or with LT (Fig. 3a) . The MUC4 levels were similar in fold change to those we found in previous microarray data [15] . Figure 3b depicts the MUC4 gene organization including multiple EGF-ligand-like repeats in the MUC4b subunit. Quantitative real-time PCR (qPCR) using primers located near one of these EGF-ligand-like repeats revealed increased mRNA levels in the treatment resistant tumors to endocrine alone or with LT when compared to E2-stimulated controls or growth-inhibited tumors harvested after 3-day treatment with ED ± LT and Tam ? LT (Fig. 3c) . These elevated MUC4 levels in the resistant tumors were similar to those detected in MUC4-overexpressing CD18/ HPAF pancreatic cancer cells (positive control). EDresistant tumors had a striking 179-fold increase in MUC4 mRNA level compared to sensitive tumors (p \ 0.001). ED ? LT-resistant tumors had a 34-fold increase in MUC4 mRNA compared to sensitive tumors (p \ 0.01), while Tam ? LT-resistant tumors had a 31-fold increase compared to sensitive tumors (p = 0.06).
MUC4 protein expression by IHC
Using the 8G7 clone of anti-MUC4 (Fig. 3b) , we detected increased MUC4 (p \ 0.005) in Tam-stimulated MCF7/ HER2-18 tumors in comparison to little to no signal in E2-stimulated MCF7/HER2-18 or MCF7/wild-type tumors (Fig. 4a) . As expected, the MUC4-overexpressing CD18/ HPAF control cells were also strongly IHC positive. MUC4 expression was also increased in the ED-resistant tumors when compared to sensitive tumors. In most cases, MUC4 staining was mostly intracellular with scant membranous staining, which was similar to staining of CD18/HPAF cells. To rule out clonal effects, we assayed MUC4 expression by IHC in xenograft tumors established from a different HER2-overexpressing MCF7 clone (MCF7/ HER2-11, [13] ) that were Tam-stimulated, ED-resistant, or E2-stimulated. Similar to our results in the MCF7/HER2- 18 clone, we detected upregulation of MUC4 protein in Tam-stimulated and ED-resistant tumors but not E2-stimulated tumors (Fig. 4b) . Mimicking the mRNA results, higher levels of MUC4 protein were also found in ED ? LT-and Tam ? LT-resistant MCF7/HER2-18 tumors but not in tumors in the therapy-sensitive stage. In contrast, in E2 ? LT-treated tumors, both the sensitive and the resistant tumors had little or no MUC4 expression.
Overall, the histoscores of ED and ED ? LT-resistant tumors were higher than sensitive tumors (p \ 0.01,\0.04, respectively), but not in E2 ? LT-treated tumors (Fig. 4c) . Sensitive tumors tended to have low percentages (\10 %) of MUC4 staining that were observed as occasional clusters of MUC4-positive cells (Fig. 4d) . Interestingly, these focal regions of positivity had moderate to very intense staining similar to those found in resistant tumors (Fig. 4d, e) .
Molecular signaling of MCF7/HER2-18 resistant tumors
To further understand the signaling pathways activated in these resistant mucinated tumors, we used western blotting analysis of protein extracts from the same Tam ? LT and ED ? LT tumors used for qPCR analysis (Fig. 5a) . Tumors in the growth-inhibited sensitive phase of both the treatments showed lower MUC4, p-HER2, total HER2, and p-MAPK protein levels, but markedly increased ER levels, compared to E2-stimulated controls. Protein levels of the ER-dependent gene product progesterone receptor (PR) were lower in ED ± LT-sensitive tumors, an expected result in an estrogen-deprived environment.
However, once these tumors acquired resistance, their molecular profile shifted. Resistant tumors has higher HER2 protein levels (p = 0.047 and \0.002 for ED ? LT and Tam ? LT, respectively) (Fig. 5b) , and striking increases of MUC4, p-HER2, and p-MAPK. p-Akt levels were also higher in Tam ? LT-resistant tumors. Resistant tumors had markedly decreased ER levels in Tam ? LTresistant tumors, with ER almost undetectable in ED ? LT-resistant tumors (p = 0.013 and \0.004, respectively, Fig. 5c ) with PR protein expression similar to results in tumors resistant to ED alone [11] .
Co-staining of MUC4 and HER2
As this molecular shift from ER-positive to ER-negative and upregulation of HER2 in resistant tumors could be associated with MUC4 expression, we investigated coexpression of MUC4 and HER2 in these tumors. We first co-stained by IHC serial sections of Tam ? LT-, ED ? LT-, and E2 ? LT-resistant tumors for both the ER/ HER2 and the MUC4/HER2. In Tam ? LT-resistant tumors, the majority of cells showed an inverse relationship between ER and MUC4. ER-negative regions were strongly HER2-positive and MUC4-positive, while a small focus of ER-positive cells in this tumor had modest HER2 expression and lacked MUC4 expression (Fig. 6a) . ED ? LT-resistant tumors, which completely lose ER expression, have more homogenous expression of MUC4 in HER2-positive regions. In contrast, E2 ? LT-resistant tumors, which have higher ER and lower HER2 levels, completely lack MUC4 expression (Fig. 6a) . We further investigated MUC4 and HER2 co-expression at the cellular level with IF and confocal microscopy in ED ? LTresistant tumors. There was a substantial fraction of HER2-positive cells that also express MUC4 (Fig. 6b) .
Discussion
In our study, resistance to ER and HER2-targeted therapies in ER-positive/HER2-overexpressing MCF7/HER2-18 xenograft tumors is associated with upregulation of mucinfilled vacuoles. This is the first breast cancer model to show endogenous upregulation of mucins, and especially MUC4, in response to therapy. The mucin family of genes has been hypothesized to be associated with drug resistance in cancer. While normally found in the epithelium of the GI tract and respiratory tree, mucin expression is common in multiple cancers [26] . One mucin in particular, mucin4 (MUC4) is overexpressed in various cancers [27] [28] [29] [30] [31] [32] [33] [34] [35] .
There are few studies of MUC4 in breast cancer, although recent preclinical data suggest that MUC4 regulates tumor cell survival and metastasis [36, 37] . The rat form of MUC4 can form a potent signaling complex with HER2 through EGF-ligand-like domains [38, 39] . MUC4 is thought to have two potential mechanisms of HER2-resistance: enhancement of HER2-HER3 signaling [40, 41] or interference with trastuzumab binding [42] . Studies in pancreatic, gall bladder, and melanoma cancer cell lines suggest that HER2 and MUC4 form a complex in HER2 non-overexpressing cell lines [24, 39, 43] . Most of these previous studies have focused on MUC4 expression in vitro. While we found MUC4 and HER2 coexpression in our xenograft tumors, MUC4 expression was mostly cytoplasmic and did not stain most mucin vacuoles. While we focused this study on MUC4, other mucins were also observed to be upregulated, including secreted mucins that may stain the mucin vacuoles. A common trigger, such as stress response or cytokine signaling, which have been previously reported to upregulate MUC4 expression in cell lines [44] [45] [46] [47] [48] , may be responsible for the mucinated phenotype.
MUC4 regulation in breast cancer is not well understood. The MUC4-expressing cell line JIMT-1 has low levels of HER2 expression with low p-HER2. Another study suggests that MUC4 is downstream of MAPK signaling, functioning through the Ets transcription factor PEA3 [49] . Interestingly, while we did not detect an increase in PEA3 by microarray, two Ets-related factors (ELF1 and ETV6) were upregulated in resistant tumors [15] . High HER2 activity activates MAPK; Tam ? LT and ED ? LT-treated tumors had activation of HER2 and MAPK in resistant tumors compared to sensitive tumors. Tumors treated with E2 ? LT have levels of MUC4 similar to E2-stimulated controls, showing that LT alone is insufficient to induce MUC4 expression and suggesting that the mucinated phenotype is not found when estrogen signaling remains active.
Our data suggests that ER may instead have a repressive role, as loss of ER coincides with increased MUC4. Alternatively, increased growth factor signaling decreases ER expression and activity [50, 51] , and mucin upregulation could be related to HER2 reactivation and MAPK signaling. Although MCF7 wild-type tumors acquire endocrine resistance by upregulating HER1/HER2 signaling [3, 11] , they fail to upregulate MUC4. This implies that a threshold HER2 level may be needed to upregulate MUC4, as MCF7/HER2-18 stably overexpresses HER2 48 times higher than MCF7 parental cells [13] .
This preclinical model has shown an interesting phenotype associated with anti-HER2 treatment and endocrine resistance. In the ED ? LT and Tam ? LT therapy-sensitive phase of growth, HER2 is inhibited but ER signaling is still partially active. Conversely, resistance to ED ? LT and Tam ? LT, similar to ED-and Tam-resistant tumors, is associated with a molecular shift away from ER signaling but with reactivation of HER2. Whether MUC4 overexpression is the cause or a contributor to reactivation of the HER2 pathway and drug resistance is unknown. Nonetheless, based on the known cellular biology of MUC4 there is a conceptual context to investigate MUC4 as a mechanism of resistance. MUC4 has been shown in pancreatic and ovarian cancer cells to increase tumor cell proliferation, motility, and tumorigenicity [52] [53] [54] . We have been unable to examine the role of MUC4 in acquired resistance in clinical samples, as resistant tumors from human trials of L ? T or ED in the presence of HER2-positive disease are currently unavailable; however, these studies are warranted as samples will become available. In summary, this study describes a novel mucinated phenotype seen in conjunction with a shift in the intimate crosstalk between ER and HER2 resulting in an ERnegative/HER2-positive tumor with reactivation of HER signaling and treatment resistance [3, 11, 55] . Upon acquiring resistance to therapy, the molecular profile of these tumors exhibits ER plasticity as it changes its phenotype to ER-negative/PR-negative/HER2-positive; the HER2 pathway is reactivated and there is marked upregulation of several mucins, including MUC4. 
